Our Services
Medical Information
Helpful Resources
Published on: 8/18/2026
PHEX gene mutations cause X-linked hypophosphatemia (XLH), a lifelong condition in which faulty PHEX signaling allows FGF23 to build up and force the kidneys to leak phosphate into the urine instead of reabsorbing it. Inheritance follows an X-linked dominant pattern, so an affected mother has a 50% chance of passing the mutation to each child while an affected father passes it to all daughters and none of his sons, though many cases arise from new mutations with no family history at all. Because phosphate is lost continuously from infancy onward, bones and teeth cannot mineralize properly, resulting in rickets, bowed legs, short stature, bone and joint pain, dental abscesses, and hearing changes that continue into adulthood. Severity varies widely even among relatives carrying the identical mutation, so inheritance alone does not predict how symptoms will present, and there are several important factors to consider before drawing conclusions, all explained below.
If you recognize these patterns in yourself or your child, the fastest way to organize what you are noticing is a free, instant, online symptom check, which turns vague concerns like leg pain, delayed growth, or repeated dental infections into a clear summary you can bring to a doctor, helping you ask about phosphate testing and reach the right specialist sooner rather than after years of uncertainty.
Last reviewed for medical accu
X-linked hypophosphatemic rickets osteomalacia (XLH) is a genetic condition marked by low phosphate levels that can lead to soft bones, leg deformities in children and bone pain or fractures in adults. At the heart of XLH is a mutation in the PHEX gene, which disrupts how your body handles phosphate—a mineral essential for bone strength. Below, we explain in plain language how PHEX gene mutations are inherited, how they cause ongoing phosphate loss, and what this means for you or a loved one.
When PHEX doesn’t work properly, FGF23 levels stay too high. The kidneys then dump too much phosphate into the urine, leaving too little in the blood for healthy bone mineralization.
XLH follows an X-linked dominant pattern:
This pattern means XLH often appears in multiple generations, although severity can vary even within the same family.
Over time, the ongoing phosphate deficit leads to weaker bones that can bend, fracture or cause pain.
Children (Rickets):
Adults (Osteomalacia):
Because the underlying problem is lifelong, symptoms can persist or recur without ongoing management.
A combination of clinical, laboratory and genetic tools is used:
Early diagnosis allows for earlier intervention, which can improve growth in children and reduce bone pain in adults.
There is no cure for XLH, but treatments aim to normalize phosphate levels and support bone health:
• Conventional therapy
• Targeted therapy
• Supportive measures
Your doctor will tailor treatment based on age, severity, response and any side effects.
A proactive approach helps you stay as active and comfortable as possible.
XLH can vary widely from person to person. Be alert to:
If any of these occur, you might consider doing a free, online symptom check, using the doctor approved Ubie Symptom Checker to guide your next steps.
Genetic counseling may help affected families understand inheritance risks and guide family planning.
Speak to your doctor about any serious symptoms or concerns. Early recognition and treatment can help reduce complications and improve quality of life.
(References)
* Insogna KL, Briot K, Imel EA, Kamenický P, Ruppe MD, Portale AA, Weber T, Pitukcheewanont P, Cheong HI, Jan de Beur S, Imanishi Y, Ito N, Lachmann RH, Tanaka H, Perwad F, Zhang L, Chen CY, Theodore-Oklota C, Mealiffe M, San Martin J, Carpenter TO, AXLES 1 Investigators. A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis. J Bone Miner Res. 2018 Aug;33(8):1383-1393. doi: 10.1002/jbmr.3475. Epub 2018 Jun 26. PMID: 29947083.
* Christov M, Jüppner H. Phosphate homeostasis disorders. Best Pract Res Clin Endocrinol Metab. 2018 Oct;32(5):685-706. doi: 10.1016/j.beem.2018.06.004. Epub 2018 Jun 18. PMID: 30449549.
* Bitzan M, Goodyer PR. Hypophosphatemic Rickets. Pediatr Clin North Am. 2019 Feb;66(1):179-207. doi: 10.1016/j.pcl.2018.09.004. PMID: 30454743.
* Imel EA, Glorieux FH, Whyte MP, Munns CF, Ward LM, Nilsson O, Simmons JH, Padidela R, Namba N, Cheong HI, Pitukcheewanont P, Sochett E, Högler W, Muroya K, Tanaka H, Gottesman GS, Biggin A, Perwad F, Mao M, Chen CY, Skrinar A, San Martin J, Portale AA. Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. Lancet. 2019 Jun 15;393(10189):2416-2427. doi: 10.1016/S0140-6736(19)30654-3. Epub 2019 May 16. PMID: 31104833; PMCID: PMC7179969.
* Rush ET, Johnson B, Aradhya S, Beltran D, Bristow SL, Eisenbeis S, Guerra NE, Krolczyk S, Miller N, Morales A, Ramesan P, Sarafrazi S, Truty R, Dahir K. Molecular Diagnoses of X-Linked and Other Genetic Hypophosphatemias: Results From a Sponsored Genetic Testing Program. J Bone Miner Res. 2022 Feb;37(2):202-214. doi: 10.1002/jbmr.4454. Epub 2021 Nov 10. PMID: 34633109; PMCID: PMC9298723.
* Miller WL, Imel EA. Rickets, Vitamin D, and Ca/P Metabolism. Horm Res Paediatr. 2022;95(6):579-592. doi: 10.1159/000527011. Epub 2022 Nov 29. PMID: 36446330.
* Kamenický P, Briot K, Munns CF, Linglart A. X-linked hypophosphataemia. Lancet. 2024 Aug 31;404(10455):887-901. doi: 10.1016/S0140-6736(24)01305-9. Epub 2024 Aug 21. PMID: 39181153.
* Haffner D, Emma F, Seefried L, Högler W, Javaid KM, Bockenhauer D, Bacchetta J, Eastwood D, Biosse Duplan M, Schnabel D, Wicart P, Ariceta G, Levtchenko E, Harvengt P, Kirchhoff M, Gardiner O, Di Rocco F, Chaussain C, Brandi ML, Savendahl L, Briot K, Kamenický P, Rejnmark L, Linglart A. Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat Rev Nephrol. 2025 May;21(5):330-354. doi: 10.1038/s41581-024-00926-x. Epub 2025 Jan 15. PMID: 39814982.
* Khan AA, Ali DS, Appelman-Dijkstra NM, Carpenter TO, Chaussain C, Imel EA, Jan de Beur SM, Florenzano P, Abu Alrob H, Aldabagh R, Alexander RT, Alsarraf F, Beck-Nielsen SS, Biosse-Duplan M, Cohen-Solal M, Crowley RK, Dandurand K, Filler G, Friedlander L, Fukumoto S, Gagnon C, Goodyer P, Grasemann C, Grimbly C, Hussein S, Javaid MK, Khan S, Khan A, Lehman A, Lems WF, Lewiecki EM, McDonnell C, Mirza RD, Morgante E, Morrison A, Portale AA, Rhee Y, Rush ET, Siggelkow H, Tetradis S, Tosi L, Ward LM, Guyatt G, Brandi ML. X-Linked Hypophosphatemia Management in Adults: An International Working Group Clinical Practice Guideline. J Clin Endocrinol Metab. 2025 Jul 15;110(8):2353-2370. doi: 10.1210/clinem/dgaf170. PMID: 40243526; PMCID: PMC12261105.
* Böckmann I, Haffner D. The Diagnosis and Therapy of XLH. Calcif Tissue Int. 2025 Apr 28;116(1):66. doi: 10.1007/s00223-025-01374-w. Epub 2025 Apr 28. PMID: 40295317; PMCID: PMC12037658.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.